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,e treatment of corneal endothelial dysfunction has experienced a revolutionary change in the past decades with the emergence
of endothelial keratoplasty techniques: descemet stripping automated endothelial keratoplasty (DSAEK) and descemet membrane
endothelial keratoplasty (DMEK). Recently, new treatments such as cultivated endothelial cell therapy, Rho-kinase inhibitors
(ROCK inhibitors), bioengineered grafts, and gene therapy have been described. ,ese techniques represent new lines of
treatment for endothelial dysfunction. ,eir advantages are to help address the shortage of quality endothelial tissue, decrease the
complications associated with tissue rejection, and reduce the burden of postoperative care following transplantation. Although
further randomized clinical trials are required to validate these findings and prove the long-term efficacy of the treatments, the
positive outcomes in preliminary clinical studies are a stepping stone to a promising future. Our aim is to review the latest available
alternatives and advancements to endothelial corneal transplant.
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1. Introduction
1.1. =e Evolution of Keratoplasty. Corneal endothelium is
formed by a single layer of hexagonal cells that preserve
corneal transparency by regulating the outflow of aqueous
humor (AH) to the stroma through its barrier and pump
mechanisms. It is supposed that corneal endothelial cells
(CEC) have a limited regenerative capacity in vivo as they
remain inactive in the G1 phase of the cellular cycle [1].
When there is a loss of CEC, the damage triggers a coun-
tervailing migration and an increase in the size (poly-
megathism) of the adjacent healthy CEC, resulting in a
global decrease in endothelial cell density (ECD) in order to
restore the single layer of CEC [1].
Fuchs Endothelial Dystrophy (FED) is a bilateral, spo-
radic, or autosomal dominant or corneal dystrophy that
involves a progressive loss of CEC [2, 3]. Pseudophakic
bullous keratopathy (PBK) is caused by an accelerated loss of
CEC, mainly after cataract surgery though it is also described
after other procedures [3]. Both entities are the most
common indication for keratoplasty in the USA [3]. Over
100 years, penetrating keratoplasty (PK) has been the only
surgical technique for the treatment of corneal diseases. In
the past two decades, PK has been gradually replaced by
lamellar keratoplasties for the treatment of endothelial
disorders [4–6]. Descemet stripping automated endothelial
keratoplasty (DSAEK) is an additive surgery as the donor
graft includes the DM, endothelium, and a portion of stroma
[7]. Descemet membrane endothelial keratoplasty (DMEK)
was introduced later as a finer modification of endothelial
keratoplasty (EK), and it comprises the transplantation of
the DM and endothelium [5, 6]. DMEK has proven to attain
better results in best-corrected visual acuity (BCVA) and a
faster recovery compared to PK and DSAEK [6, 8–10].
Nevertheless, this technique has reported to have a longer
learning curve than DSAEK, and a higher rate of postop-
erative graft detachment which is usually balanced after the
learning curve [10–13]. ,e use of thinner grafts in DSAEK
(<100 µm), termed ultrathin DSAEK, shows better BCVA
results compared to standard DSAEK, although it has not
proven to be superior to DMEK in BCVA results nor in
complication rates [13–17].
Recent innovations of DMEK are hemi-DMEK [18] and
quarter-DMEK [19]. Hemi-DMEK consists of 12mm
long× 5mm wide semilunar-shaped grafts, proving an
equivalent surface and postoperative ECD of a standard
round 8mm DMEK graft [20]. Quarter-DMEK comprises
6× 5mm grafts shaped as a quarter of a circle and has proven
an equivalent surface and postoperative ECD to a 6mm
DMEK graft [21] (Figure 1). Although it is not authorized in
all countries, the possible advantage of these techniques is to
provide higher availability of endothelial donor tissues
[21, 22]. Both techniques proved similar postoperative
BCVA results, although ECD was lower than a standard
DMEK [23–25]. However, BCVA remained stable after three
years in hemi-DMEK and after two years in quarter-DMEK
procedures [23–25]. Both techniques, especially quarter-
DMEK, could be reserved for cases of central FED and
patients with different anterior chamber (AC) abnormalities,
such as peripheral anterior synechiae or the presence of
glaucoma valve implants.
Another technique termed descemet membrane endo-
thelial transfer (DMET) was developed after observing
corneal clearance despite subtotal graft detachment in pa-
tients operated for DSAEK or DMEK [26, 27]. In this
procedure, the DMEK graft is introduced into the AC as a
free-floating graft roll attached to the receptor cornea only
by the main incision where the graft was introduced [28]
(Figure 2). Interestingly, spontaneous clearance despite graft
detachment only occurred in patients with FED and not in
those with PBK [29]. Peripheral endothelium is relatively
conserved in FED; hence, a migratory endothelial response
of functioning peripheral cells could occur despite the graft
not being completely attached [29]. Nevertheless, the cell
regenerative capacity of FED patients might not be enough
to guarantee permanent corneal transparency, as corneal
decompensation six months after DMET has been reported
[29].
2. Alternatives to Tissue Grafting
2.1. Descemetorhexis without Endothelial Keratoplasty
(DWEK)/Descemet Stripping Only (DSO). Some FED pa-
tients have reported corneal clearance by simply performing
descemetorhexis intentionally or unintentionally [30]. ,e
technique was named descemetorhexis without endothelial
keratoplasty (DWEK) by Kaufman in 2018 [31] and was also
called descemet stripping only (DSO) by Gorovoy [7]
(Figure 2). However, the original idea was first described by
Paufique in 1955 [32].
,is technique is based on the assumption that the
remaining peripheral CEC could migrate onto the denuded
central stroma [30, 33, 34]. As mentioned priorly, CEC have
a limited regenerative capacity in vivo [35–37]. ,erefore, it
is generally believed that endothelial wound healing occurs
through cell migration rather than the proliferation of new
cells [34]. However, stem cell markers (LGR5) have been
identified in the posterior limbus near the trabecular
meshwork [35–37], hence suggesting that some endothelial
stem cells may be involved in endothelial wound repair
[30, 34, 38].
A series of cases by Koenig, Bleyen et al., and Arbelaez
et al. [30, 33, 39] described failure or inconclusive results of
DSO after an 8mm, 6–6.5mm, and 6mm descemetorhexis,
respectively. It was hypothesized that the rough zone could
have been somehow linked to the disfunction and/or the
damage of endothelial cells due to surgical trauma [32, 39].
Corneal clearance has been reported after performing a
smaller descemetorhexis (4mm) in the following studies:
Ioveno et al. [40], in four out of five cases; Borkar et al. [41],
in 10 out of 13 eyes; and nine out of 12 in the series of
Garcerant et al. [32]. ,us, it seems that DSO achieves better
results when descemetorhexis is performed with a smaller
size [32, 40, 41].
An increase in the descemetorhexis diameter from 4 to
6mm requires more than double the surface area for the
remaining endothelium to repopulate, whereas an 8mm
descemetorhexis requires a repopulation of four times the




Figure 2: (a, b) Fuchs endothelial dystrophy disease with guttae protruding from the descemet membrane (DM). (a, c, e) ,e DMET
technique. After descemetorhexis, the graft is inserted and fixated to the main corneal incision; the rest of it remains free-floating in the
anterior chamber. (d),e DWEK/DSO technique in which a descemetorhexis is performed without further graft implantation. (b, d, f ) ,e
DMT technique in which descemetorhexis is performed and a DM graft devoid of endothelial cells is transplanted (based on the articles by
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Figure 1: Comparison of graft diameter in DMEK (8.5 to 9.5mm), hemi-DMEK (11-12mm× 5-6mm), and quarter-DMEK (6mm× 5mm)
(based on the articles by Lam et al. and Müller et al. [19, 28]).
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area of a 4mm descemetorhexis [40]. Consequently, DSO
would be better reserved for patients with central and
nondecompensated FED, with a good peripheral CEC res-
ervoir (over 1,000 cells/mm2), considering the relatively low
postoperative central CEC count described [40–42]. Borkar
et al. [41] reported that corneal transparency was achieved in
different time periods after undergoing DSO. ,ese periods
were as follows: from after one to three months (fast re-
sponders), after six months (slow responders), and unsuc-
cessful surgeries that required EK (no responders).
,ere is some disagreement among ophthalmologists
whether a secondary EK performed after an unsuccessful
DSO could achieve favorable results. Both Rao et al. and
Moloney et al. [43, 44] reported positive outcomes.
,erefore, DSO may not hinder the outcome of a secondary
EK if necessary [32]. However, some authors, such as
Arbelaez et al. [39], suggested that a subsequent DMEK graft
may not easily adhere to areas that were stripped off and then
repopulated with the endothelium, unless the repopulated
endothelial cell layer is removed. Future prospective studies
are required to confirm these findings.
Combination of DSO with cataract surgery does not
seem to affect the results, hence being a viable option
[31, 32, 40–42]. Borkar et al. [41] stated that approximately
75% of eyes that had combined DSO and cataract with IOL
placement surgery showed corneal clearance and repopu-
lation of the central endothelial mosaic by confocal
microscopy.
However, the results of DSO are inconsistent as some
studies have reported the failure of this technique in
achieving corneal transparency [40, 45]. It is reasonable to
suppose that surgery outcomes may depend on patients’
innate features, possibly genetic, that involve CECmigration
ability, anterior segment configuration, and surgery-related
factors [32]. For instance, Davies et al. [45] stated that
achieved corneal transparency time period after DSO in the
fellow eye was observed to happen in the similar time period
as the first eye, suggesting that patients’ innate factors, such
as growth factors in the AC, could be involved although they
are yet to be defined [32, 45]. It is possible that differences in
the number of trinucleotide repeated expansions in FED
patients may affect the success or failure of DSO [41]. It is
worth mentioning that an in vitro analysis of endothelial cell
migration by Soh et al. [46] identified that younger ages and
intact DM are important factors that may promote cell
migration.
Soh et al. [46] found that CEC migrate more efficiently
over a denuded but intact DM compared to bare stroma.
Similarly, Garcerant et al. [32] described posterior stromal
scarring in the edematous zone during the corneal clearance
process in slow responders or nonresponders. ,erefore,
they assumed that surgical trauma of the stroma could
induce an unpredictable healing response favoring fibrosis,
hence recommending a surgical procedure that avoids
stromal contact.,ey recommend using a peeling technique,
to maximize both cell preservation and migration [32], as
they observed an increased cell loss in techniques where
constant pressure was applied during Descemet’s scoring.
,is theory is supported by Davies et al. [45], who observed
that DSO performed with a 360-degree scoring technique
resulted in a visually significant stromal scarring, either from
the scoring itself or from persistent edema. ,is group
described that all failed cases in healing after DSO shared the
360-degree scoring technique followed by stripping. Nev-
ertheless, all cases that underwent stripping by peeling
without scoring cleared successfully [32, 45]. ,ey proposed
that manual stripping can result in an irregular DM border
that promotes small DM detachments and edema [45].
Macsai and Shiloach [47] recommended attempting a
smooth transition edge without any interruptions of sub-
jacent stromal fibers by a slow and steady aspiration using
the irrigation/aspiration handpiece connected to the
phacoemulsification unit. ,e DM should be torn in a
curvilinear fashion such as the capsulorhexis technique in
cataract surgery.
Regarding postoperative visual quality, Garcerant et al.
[32] had the following theory explaining irregular astig-
matism despite corneal clearance [40]. First, they described
central corneal thinning in cases that attained corneal
clearance [32, 46]. It is known that any corneal procedure
that leads to central corneal thinning may simulate a myopic
ablation, and a small or off-centered optic zone may induce
higher-order aberrations [32]. It is therefore hypothesized
that off-centered descemetorhexis could act as an off-cen-
tered optical zone and be the cause of visual disturbances.
,us, it is highly recommended to attempt symmetry and to
meticulously center the procedure [32]. Lastly, performing
relaxing incisions in DM may possibly have an astigmatic
effect [32].
Regarding BCVA, DSO has proven to be successful in
some patients: Borkar et al. [41] reported BCVA between
−0.12 and 0.00 LogMAR. Davies et al. [45] achieved corneal
clearance in 14 (82.4%) eyes, with a corneal edema reso-
lution meantime from 3.14 to 6.17 months. Out of the 14
eyes cleared, 13 eyes achieved a BCVA of 20/25.
Huang et al. [42] compared visual outcomes of 12 DSO
with 15 DMEK cases in mild to moderate FED. Although
meantime to achieve 20/40 vision was longer for DSO than
DMEK cases (2.2± 2.8 weeks compared to 7.1± 2.7 weeks,
respectively), they found no statistical differences in final
BCVA with less rate of adverse events in the DSO group.
Huang et al. [42] did not provide ECD comparison between
the two groups. ,erefore, their conclusion [42] of relatively
similar results among both DSO and DMEK should be taken
cautiously.
As a donor graft is not necessary, the short-term (graft
detachment and postoperative elevated intraocular pressure
(IOP) due to topical steroid treatment or air bubble
placement) and long-term complications (rejection, glau-
coma, secondary cataract, potential disease transmission, or
infectious keratitis) are reduced. On the other hand, lower
postoperative ECD has been reported following this tech-
nique [39].
,erefore, despite contradictory outcomes, it may be
reasonable to include DSO as a potential technique to treat
endothelial disorders, especially for the treatment of central
FED. It would be useful in areas with difficult access to donor
grafts, in personal circumstances that could force patients to
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refuse graft surgery or when side effects of this technique
outweigh the benefits. Although longer follow-up studies are
needed, a recent retrospective case report of a successful and
stable 5-year, bilateral DSO [48] suggested stability in the
short term.
2.2. Descemet Membrane Transplantation (DMT).
Primary descemetorhexis followed by acellular descemet
membrane transplantation (DMT) [49] is a recently intro-
duced technique for FED patients. Although donor tissue is
required, no donor CEC are needed for DMT, whichmajorly
increases the donor pool and decreases the risk of rejection.
Similar to DSO, it seems to work better with smaller stripped
areas that leave peripheral CEC intact (Figure 2).
3. ROCK Inhibitors
RhoA/Rho-kinase (ROCK) intracellular pathway plays a role
in actin cytoskeleton regulation and actomyosin contractile
forces [50, 51], as well as numerous cellular processes that
include cell proliferation (especially cell cycle progression),
migration, adhesion, rigidity, morphology, apoptosis, and
extracellular matrix reorganization [35, 36, 50–53]. ,e
effect of ROCK pathway signaling seems to be dependent on
each type of cell.
ROCK signaling is involved in numerous pathologies
such as vascular diseases, cancer, asthma, insulin resistance,
renal insufficiency, osteoporosis, neuronal degenerative
diseases, and glaucoma [35, 52].,us, ROCK inhibitors have
been conceived as a therapeutic target for the treatment of
several conditions [35, 52].
Regarding glaucoma, ROCK inhibitors alter trabecular
meshwork configuration, increasing AH outflow through
the trabecular pathway, hence decreasing IOP [43]. Two
ROCK inhibitors have been approved for the treatment of
ocular hypertension and glaucoma: ripasudil (Glanatec™)
and netarsudil (Rhopressa™) [53].
3.1. ROCK Inhibitors and Corneal Endothelium. CEC have
proliferative activity in vitro, implying that corneal endo-
thelium could proliferate under appropriate conditions
[36, 52, 53]. ,e latest evidence supports that ROCK in-
hibition stimulates in vivo CEC proliferation, as well as
cellular migration and apoptosis suppression [35]. ,ere-
fore, ROCK signaling modulation could be a potential
therapeutic target for the early phase of the corneal endo-
thelial disease [35–37, 52–54].
3.2. Studies inAnimals. Okumura et al. [55, 56] reported that
ROCK inhibitor Y-27632 increased cellular proliferation in
vitro of cultivated CEC in primates. Later on, both Koizumi
et al. and Okumura et al. [54–56] from the Kinoshita group
proved its use in in vivo corneal endothelial dysfunction
models in rabbits [55, 56] and primates [52]. ,ey dem-
onstrated that topical Y-27632 improved ECD, corneal
edema, wound size, and scarring of endothelial wounds.
,ey also confirmed that CEC proliferation in rabbits
increased in a dose-dependent pattern after the instillation
of Y-27632.
3.3. Studies on Humans. ,e efficacy of Y-27632 for the
treatment of central corneal edema caused by FED has
recently been investigated [36, 53, 54]. Koizumi et al. [54]
carried out a study observing a stable reduction in central
corneal thickness in three out of four eyes after topical
Y-27632 application six times a day for one week. Similarly,
Okomura et al. [53] found a recovery of corneal transpar-
ency in eight patients after being treated with topical
Y-27632. ,ese findings suggest that topical Y-27632 could
be clinically beneficial for patients with central corneal
edema secondary to FED [36, 53].
In both the studies mentioned above [53, 54], there were
four cases of diffuse edema related to PBK that did not show
a decrease in corneal thickness or any improvement in
BCVA, despite the treatment with Y-27632.
Consequently, these findings suggest that topical
Y-27632 could be clinically beneficial for patients with
central corneal edema caused by FED, with less evidence in
PBK [53, 54].
3.4. ROCK Inhibitors Combined with DSO. DSO in combi-
nation with topical ROCK inhibitors could improve BCVA
results and may obviate or delay EK, therefore optimizing
endothelial graft donor availability. Endothelial restoration
without donor tissue could reduce higher-order aberrations
and dispersion that often reduce BCVA after EK caused by
the donor-receptor interface, mainly in DSAEK [47, 57, 58].
Soh et al. [46] found that Y-27632 supplementation may
counterbalance the negative effect of older age in CEC
migration.
Koizumi et al. [36] were the first to report the resolution
of corneal edema caused by FED with the combination of
endothelial denudation by transcorneal freezing and topical
ROCK inhibitors. Macsai and Shiloach [47] studied the use
of ROCK inhibitors in patients with FED with a peripheral
corneal reserve >1,000 cells/mm2 that underwent DSO. In
this study, nine patients were treated with ripasudil after
DSO and another nine patients only underwent DSO. ,e
use of ripasudil resulted in a faster BCVA recovery, higher
central ECD after a year of treatment, and a decrease of
peripheral ECD loss. Patients in the control arm showed a
reduction in peripheral ECD by 10% after one year of
treatment. Interestingly, the treatment arm showed no
significant differences in peripheral ECD compared to
preoperative values. ,e fact that the group treated with
ripasudil revealed a postoperative ECD equivalent to pre-
operative ECD supports the concept of peripheral endo-
thelial cell proliferation and/or migration after combining
DSO with ripasudil.
DSO combined with ripasudil could imply an eco-
nomical saving for society, as it does not require donor tissue
normuch postoperative care. Moreover, Davies [59] recently
observed that netarsudil could be effective in achieving
corneal clearance in different cases of endothelial dys-
function that may present in a daily cornea practice, such as
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iridocorneal endothelial syndrome, after an early PK graft
failure and after a chronic PK graft failure. Likewise, this has
recently been verified by Schlötzer-Schrehardt et al. [60] in a
large database with an ex vivo FECD tissue culture model,
where a single dose of ripasudil induced a significant
upregulation of genes and proteins related to cell cycle
progression, adhesion, and migration of the cellular matrix,
as well as increasing the endothelial pump and barrier
function up to 72 hours after instillation without inducing
adverse phenotypic changes.
3.5. ROCK Inhibitors and Cell =erapy. Tissue engineering
has been suggested as a novel therapy that could replace
conventional corneal transplantation [61, 62]. ,ere are two
possible available strategies to transplant cultivated CEC in
receptor corneas: scaffold-based and cell-based [61, 62].
Scaffold-based strategy is based on transplanting cultivated
corneal endothelium on a vector plate in a similar procedure
to EK [35, 63]. Okumura et al. and Koizumi et al. [53, 63] and
other researchers [64–66] have cultivated CEC on specific
substrates. Examples of substrates are amniotic membrane
[67], DM, human anterior lens capsule [68, 69], and bio-
engineered matrices composed of compressed collagen [70],
gelatin [71, 72], silk-fibroin, and a combination of bio-
polymers. Subsequently, the resulting CEC sheets have been
transplanted in animal models observing corneal clearing.
However, these sheets are composed of a fragile single layer
of cells and its attachment to the receptor requires a rela-
tively challenging surgical technique [35].
Cell-based strategy is based on injecting cultivated CEC
into the AC in the form of cell suspension. Okomura et al.
[62] defended that cellular injection has certain advantages.
For instance, it is a simple, noninvasive, and easy to prepare
procedure. ,e injected CEC in the AC would not spon-
taneously attach to the receptor corneal endothelial layer,
but ROCK inhibitors are known to improve the adhesion of
CEC to a substrate [55]. ,is led researchers to pioneer
animal experiments that proved the safety and efficacy of
cultivated CEC injections in combination with ROCK in-
hibitors [35–37].
Kinoshita et al. [73] carried out a study on humans
with a two-year follow-up. ,ey included 11 patients,
seven with FED and the rest with bullous keratopathy
(BK) of various causes. A mechanic 8 mm descemeto-
rhexis followed by an injection of cultivated CEC in
combination with ROCK inhibitor Y-27632 was per-
formed. After the procedure, the patients rested in a
prone position for three hours (Figure 3). After six
months, ECD >500 cells/mm2 was observed in all pa-
tients, and 10 out of 11 had an ECD >1,000 cells/mm2.
Regarding visual outcomes, nine out of 11 showed a
BCVA equal to or higher than 0.3 LogMAR. Furthermore,
10 out of 11 patients revealed a central corneal thickness
<630 μm. Two years after the procedure, all the corneas
remained transparent, with an average ECD of
1,534 cells/mm2, and nine out of 11 patients had a BCVA
equal or higher than 0.1 LogMAR.
,e authors hypothesized a few concerns, namely, what
happened to the CEC that did not attach to the receptor en-
dothelium and whether it could obstruct the trabecular
meshwork or lead to iris adhesions. Another concern was that
CEC could pass onto the systemic circulation and could po-








DWEK/DSO + ROCK inhibitors
+ suspension CEC
DWEK/DSO ± ROCK inhibitors
ROCK inhibitors
Less advanced More advanced
Figure 3: Schematic images of cultivated endothelial corneal cells (CEC) injected in the anterior chamber (AC) therapy. (a) CEC injected
with a ROCK inhibitor in the AC; (b) prone position to help in the adherence of the cultivated CEC to the recipient stroma; (c) prone
position should be maintained for three hours postoperatively; and (d) regeneration of the corneal endothelium by the injected CEC (based
on the article by Okumura et al. [62]).
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latest evidence, ROCK inhibitors and cell therapy can effectively
be used in both FED and BK patients with optimal results
(Figure 4).
Other substances that are currently being investigated
for the treatment of endothelial diseases are antioxidants,
such as N-acetylcysteine, coenzyme Q-10, sulforaphane [74],
RTA-408 [75], and fibroblast growth factors, such as FGF-1
and bioengineered eFGF synthesized by Trefoil™.
4. Gene Therapy
Two types of gene therapy could play an important role in
corneal diseases: antisense oligonucleotides (ASO) and
prokaryotic clustered regularly interspaced palindromic
repeats (CRISPR) [76, 77].
An ASO molecule consists of a small sequence of nu-
cleotide fragments complementary to a specific gene
(a) (b)
(c) (d)
Figure 4: Future strategies for the treatment of endothelial diseases, from less invasive treatments to more invasive ones (based on the article
by Okumura et al. [35]).
(a) (b) (c)
Figure 5: EndoArt® device in the first-in-human trial: (a) corneal edema prior to implantation. (b) ,e same eye on the first postoperativeday. Note the air bubble at the AC that works as a tamponade agent. (c) Another eye several weeks following implantation. ,e central area
corresponding to the implant zone is transparent, whereas the periphery outside the implant borders is edematous.
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sequence (messenger RNA, mRNA). In antisense therapy,
base pairing between the ASO molecule and mRNA inhibit
gene translation hence disabling protein synthesis. ,e
CRISPR are a defense mechanism against virus present in
bacteria and archaea. ,ey consist of a palindromic short
sequence DNA, originated from the virus that has previously
infected these bacteria. ,ese DNA loci are usually associ-
ated with Cas genes that code a type of nuclease (enzymes
that can split DNA). CRISPR spacers recognize specific
sequences and guide Cas nuclease to split and degrade
exogenous genic elements [77]. ,us, when a virus attacks a
determined bacterium, it interacts with the Cas protein
complex bound to the RNA produced by the CRISPR se-
quence. ,en, the viral genetic material gets inactivated,
degraded, modified, and integrated in the CRISPR sequence.
Ultimately, the defense will be more effective in case of a
future contact of the bacteria or its descendants with the
affected virus.
,e CRISPR/Cas9 system could be used to edit and
regulate the genome [78]. A RNA molecule can be designed
and inserted in the nucleus, where it recognizes the exact
genome location that the Cas9 enzyme must split. Later, a
second mechanism allows the split DNA to be repaired,
embodying the correct genetic sequence in the exact original
site of splitting [78].
Although FED is a heterogenous genetical disease, a
major number of patients, especially Caucasians, possess a
pathological trinucleotide expansion sequence (typically,
cytosine-thymine-guanin (CTG) in the TCF4 gene located in
chromosome 18q21) [76, 79]. ASO molecules targeting
specific trinucleotide expansion mRNA and CRISPR/Cas9
systems designed to bind to DNA trinucleotide repeated
sequences may interrupt these mRNA anomalous repeti-
tions that cause some subtypes of FED, especially in cases of
intermediate and short anomalous lengths [76, 80, 81].
Koenig [30] suggested that RNA toxicity contributes to
the pathogenesis of FED. Changes in the endothelial barrier
function, a known event in the development of FED, were
identified as a key biological process influenced by the
misplacing events. Moreover, anomalous DNA segments
may possibly be directly excised by endonucleases, such as
transcription activator-like effector nucleases (TALENS)
[82]. ,ese findings support that gene therapy could be
effective in treating the genetic defects responsible for some
types of FED, therefore changing the phenotype.
Recent studies have managed to administer transcription
activators Cas9 molecules in vivo in CEC in rats, stimulating
corneal endothelial proliferation and the restoration of
normal endothelium after corneal cryotherapy. ,e latest
research suggests that this technique could work on humans
by adding additional improvements [83–86].
5. Mechanic Artificial Endothelium
Endothelial dysfunction is manifested by corneal edema
caused by endothelial pump malfunction. EndoArt® is aflexible silicon sheet covered with an adhesive substance,
that is inserted into the AC and attached to the posterior
surface of the cornea by air/gas pneumopexy, similar to a
DMEK graft. ,is silicon sheet prevents the passive inflow of
electrolytes and water into the cornea while allowing water
evaporation from the corneal surface. Since this is a rela-
tively new concept and device, there are no relevant peer-
reviewed studies yet. However, the first experiments in
humans after several years of animal studies were recently
published in international meetings, showing promising
results [87, 88] (Figure 5). ,is approach may be interesting
in patients that cannot undergo EK, as a bridging procedure
from diagnosis until EK is available, or even as a substitute to
EK altogether. Nevertheless, a prospective, long-term study
is needed to verify the promising preliminary results.
6. Conclusion
In the last decades, we have witnessed a true revolution in
the treatment of corneal endothelial dysfunction. We have
gone from penetrating keratoplasty as a sole therapy for all
the corneal diseases, regardless of its origin and localization,
to the great advancement that endothelial keratoplasty (EK)
has supposed, being descemet stripping automated endo-
thelial keratoplasty (DSAEK) and descemet membrane
endothelial keratoplasty (DMEK) its two most exalted ex-
amples. ,e tenacious concept that corneal endothelial cells
(CEC) cannot proliferate in vivo has been surpassed in
recent years with research findings supporting that pe-
ripheral CEC possesses stem cell features. Similarly, many
authors have proven that it is technically possible to cultivate
and transplant CEC in both animals and humans.
Currently, we are witnessing the development of new
techniques and therapies that try to reduce complications
derived from EK: descemet stripping only (DSO), ROCK
inhibitors, cellular therapy, bioengineered grafts, gene
therapy, endothelial regeneration, and artificial endothelial
substitutes. ,ese procedures offer a new perspective in the
treatment of endothelial dysfunction. Moreover, they con-
tribute to mitigating the scarcity of quality endothelial donor
tissue and decreasing the complications derived from the
immune rejection of the donor graft, as well as reducing the
use of steroid treatment. Although additional randomized
prospective peer-reviewed trials are necessary to validate the
findings and to confirm the effectiveness and safety of these
procedures, the positive results in preliminary clinical
studies predict a promising future.
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[31] A. R. Kaufman, R. M. Nosé, and R. Pineda, “Descemetorhexis
without endothelial keratoplasty (DWEK): proposal for no-
menclature standardization,” Cornea, vol. 37, no. 4,
pp. e20–e21, 2018.
[32] D. Garcerant, N. Hirnschall, N. Toalster, M. Zhu, L. Wen, and
G. Moloney, “Descemet’s stripping without endothelial ker-
atoplasty,” Current Opinion in Ophthalmology, vol. 30, no. 4,
pp. 275–285, 2019.
[33] I. Bleyen, I. E. Y. Saelens, B. T. H. Van Dooren, and G. van Rij,
“Spontaneous corneal clearing after descemet’s stripping,”
Ophthalmology, vol. 120, no. 1, p. 215, 2013.
[34] S. B. Koenig, “Planned descemetorhexis without endothelial
keratoplasty in eyes with fuchs corneal endothelial dystro-
phy,” Cornea, vol. 34, no. 9, pp. 1149–1151, 2015.
[35] N. Okumura, S. Kinoshita, and N. Koizumi, “Application of
rho kinase inhibitors for the treatment of corneal endothelial
Journal of Ophthalmology 9
diseases,” Journal of Ophthalmology, vol. 2017, Article ID
2646904, 8 pages, 2017.
[36] N. Koizumi, N. Okumura, M. Ueno, H. Nakagawa, J. Hamuro,
and S. Kinoshita, “Rho-associated kinase inhibitor eye drop
treatment as a possible medical treatment for fuchs corneal
dystrophy,” Cornea, vol. 32, no. 8, pp. 1167–1170, 2013.
[37] K. Hirata-Tominaga, T. Nakamura, N. Okumura et al.,
“Corneal endothelial cell fate is maintained by LGR5 through
the regulation of hedgehog and Wnt pathway,” Stem Cells,
vol. 31, no. 7, pp. 1396–1407, 2013.
[38] S. L. McGowan, H. F. Edelhauser, R. R. Pfister, and
D. R Whikehart, “Stem cell markers in the human posterior
limbus and corneal endothelium of unwounded and wounded
corneas,” Molecular Vision, vol. 13, pp. 1984–2000, 2007.
[39] J. G. Arbelaez, M. O. Price, and F. W. Price, “Long-term
follow-up and complications of stripping descemet mem-
brane without placement of graft in eyes with fuchs endo-
thelial dystrophy,” Cornea, vol. 33, no. 12, pp. 1295–1299,
2014.
[40] A. Iovieno, A. Neri, A. M. Soldani, C. Adani, and L. Fontana,
“Descemetorhexis without graft placement for the treatment
of fuchs endothelial dystrophy: preliminary results and review
of the literature,” Cornea, vol. 36, no. 6, pp. 637–641, 2017.
[41] D. S. Borkar, P. Veldman, and K. A. Colby, “Treatment of
fuchs endothelial dystrophy by descemet stripping without
endothelial keratoplasty,” Cornea, vol. 35, no. 10,
pp. 1267–1273, 2016.
[42] M. J. Huang, S. Kane, and D. K. Dhaliwal, “Descemetorhexis
without endothelial keratoplasty versus DMEK for treatment
of fuchs endothelial corneal dystrophy,” Cornea, vol. 37,
no. 12, pp. 1479–1483, 2018.
[43] R. Rao, D. S. Borkar, K. A. Colby, and P. B. Veldman,
“Descemet membrane endothelial keratoplasty after failed
descemet stripping without endothelial keratoplasty,” Cornea,
vol. 36, no. 7, pp. 763–766, 2017.
[44] G. Moloney, C. Petsoglou, M. Ball et al., “Descemetorhexis
without grafting for fuchs endothelial dystrophy-supple-
mentation with topical ripasudil,” Cornea, vol. 36, no. 6,
pp. 642–648, 2017.
[45] E. Davies, U. Jurkunas, and R. Pineda, “Predictive factors for
corneal clearance after descemetorhexis without endothelial
keratoplasty,” Cornea, vol. 37, no. 2, pp. 137–140, 2018.
[46] Y. Q. Soh, G. Peh, B. L. George et al., “Predicative factors for
corneal endothelial cell migration,” Investigative Opthalmol-
ogy & Visual Science, vol. 57, no. 2, pp. 338–348, 2016.
[47] M. S. Macsai and M. Shiloach, “Use of topical rho kinase
inhibitors in the treatment of fuchs dystrophy after descemet
stripping only,” Cornea, vol. 38, no. 5, pp. 529–534, 2019.
[48] J. Artaechevarria Artieda, M. Wells, R. N. Devasahayam, and
G. Moloney, “5-year outcomes of descemet stripping only in
fuchs dystrophy,” Cornea, vol. 39, no. 8, pp. 1048–1051, 2020.
[49] M. Bhogal, C. N. Lwin, X.-Y. Seah, G. Peh, and J. S. Mehta,
“Allogeneic descemet’s membrane transplantation enhances
corneal endothelial monolayer formation and restores functional
integrity following descemet’s stripping,” Investigative Opthal-
mology & Visual Science, vol. 58, no. 10, pp. 4249–4260, 2017.
[50] A. Hall, “Rho GTPases and the actin cytoskeleton,” Science,
vol. 279, no. 5350, pp. 509–514, 1998.
[51] M. Moshirfar, L. Parker, O. C. Birdsong et al., “Use of rho
kinase inhibitors in ophthalmology: a review of the literature,”
Medical Hypothesis, Discovery & Innovation (MEHDI) Jour-
nals, vol. 7, pp. 101–111, 2018.
[52] N. Okumura, N. Koizumi, M. Ueno et al., “Enhancement of
corneal endothelium wound healing by rho-associated kinase
(ROCK) inhibitor eye drops,” British Journal of Ophthal-
mology, vol. 95, no. 7, pp. 1006–1009, 2011.
[53] N. Okumura, N. Koizumi, E. P. Kay et al., “,e ROCK in-
hibitor eye drop accelerates corneal endothelium wound
healing,” Investigative Opthalmology & Visual Science, vol. 54,
no. 4, pp. 2493–2502, 2013.
[54] N. Koizumi, N. Okumura, M. Ueno, and S. Kinoshita, “New
therapeutic modality for corneal endothelial disease using
rho-associated kinase inhibitor eye drops,” Cornea, vol. 33,
no. S11, pp. S25–S31, 2014.
[55] N. Okumura, M. Ueno, N. Koizumi et al., “Enhancement on
primate corneal endothelial cell survival in vitro by a rock
inhibitor,” Investigative Opthalmology & Visual Science,
vol. 50, no. 8, pp. 3680–3687, 2009.
[56] N. Okumura, Y. Okazaki, R. Inoue et al., “Effect of the rho-
associated kinase inhibitor eye drop (ripasudil) on corneal
endothelial wound healing,” Investigative Opthalmology &
Visual Science, vol. 57, no. 3, pp. 1284–1292, 2016.
[57] S. V. Patel, K. H. Baratz, D. O. Hodge et al., “,e effect of
corneal light scatter on vision after descemet stripping with
endothelial keratoplasty,”Archives of Ophthalmology, vol. 127,
no. 2, pp. 153–160, 2009.
[58] M. C. Carnahan and D. A. Goldstein, “Ocular complications
of topical, peri-ocular, and systemic corticosteroids,” Current
Opinion in Ophthalmology, vol. 11, no. 6, pp. 478–483, 2000.
[59] E. Davies, “Case series: novel utilization of rho-kinase in-
hibitor for the treatment of corneal edema,” Cornea, vol. 40,
no. 1, pp. 116–120, 2021.
[60] U. Schlötzer-Schrehardt, M. Zenkel, M. Strunz et al., “Po-
tential functional restoration of corneal endothelial cells in
fuchs endothelial corneal dystrophy by ROCK inhibitor
(ripasudil),” American Journal of Ophthalmology, vol. 224,
pp. 185–199, 2021.
[61] N. Okumura, S. Kinoshita, and N. Koizumi, “Cell-based
approach for treatment of corneal endothelial dysfunction,”
Cornea, vol. 33, no. S11, pp. S37–S41, 2014.
[62] N. Okumura, Y. Sakamoto, K. Fujii et al., “Rho kinase in-
hibitor enables cell-based therapy for corneal endothelial
dysfunction,” Scientific Reports, vol. 6, no. 1, 2016.
[63] N. Koizumi, Y. Sakamoto, N. Okumura et al., “Cultivated
corneal endothelial cell sheet transplantation in a primate
model,” Investigative Opthalmology & Visual Science, vol. 48,
no. 10, pp. 4519–4526, 2007.
[64] T.Mimura, S. Yamagami, and S. Amano, “Corneal endothelial
regeneration and tissue engineering,” Progress in Retinal and
Eye Research, vol. 35, pp. 1–17, 2013.
[65] D. Spinozzi, A. Miron, M. Bruinsma et al., “Evaluation of the
suitability of biocompatible carriers as artificial transplants
using cultured porcine corneal endothelial cells,” Current Eye
Research, vol. 44, no. 3, pp. 243–249, 2019.
[66] J. Navaratnam, T. Utheim, V. Rajasekhar, and A. Shahdadfar,
“Substrates for expansion of corneal endothelial cells towards
bioengineering of human corneal endothelium,” Journal of
Functional Biomaterials, vol. 6, no. 3, pp. 917–945, 2015.
[67] Y. Ishino, Y. Sano, T. Nakamura et al., “Amniotic membrane
as a carrier for cultivated human corneal endothelial cell
transplantation,” Investigative Opthalmology & Visual Science,
vol. 45, no. 3, pp. 800–806, 2004.
[68] E. Yoeruek, O. Saygili, M. S. Spitzer, O. Tatar, K. U. Bartz-
Schmidt, and P. Szurman, “Human anterior lens capsule as
carrier matrix for cultivated human corneal endothelial cells,”
Cornea, vol. 28, no. 4, pp. 416–420, 2009.
[69] N. Kopsachilis, I. Tsinopoulos, T. Tourtas, F. E. Kruse, and
U.W. Luessen, “Descemet’s membrane substrate from human
10 Journal of Ophthalmology
donor lens anterior capsule,” Clinical & Experimental Oph-
thalmology, vol. 40, no. 2, pp. 187–194, 2012.
[70] H. Levis, A. Kureshi, I. Massie, L. Morgan, A. Vernon, and
J. Daniels, “Tissue engineering the cornea: the evolution of
RAFT,” Journal of Functional Biomaterials, vol. 6, no. 1,
pp. 50–65, 2015.
[71] R. Watanabe, R. Hayashi, Y. Kimura et al., “A novel gelatin
hydrogel carrier sheet for corneal endothelial transplanta-
tion,” Tissue Engineering Part A, vol. 17, no. 17-18,
pp. 2213–2219, 2011.
[72] H. J. Levis, G. S. L. Peh, K.-P. Toh et al., “Plastic compressed
collagen as a novel carrier for expanded human corneal en-
dothelial cells for transplantation,” PLoS One, vol. 7, no. 11,
Article ID e50993, 2012.
[73] S. Kinoshita, N. Koizumi, M. Ueno et al., “Injection of cul-
tured cells with a ROCK inhibitor for bullous keratopathy,”
New England Journal of Medicine, vol. 378, no. 11, pp. 995–
1003, 2018.
[74] A. Ziaei, T. Schmedt, Y. Chen, and U. V. Jurkunas, “Sul-
foraphane decreases endothelial cell apoptosis in fuchs en-
dothelial corneal dystrophy: a novel treatment,” Investigative
Opthalmology & Visual Science, vol. 54, no. 10, pp. 6724–6734,
2013.
[75] S. A. Reisman, C.-Y. I. Lee, C. J. Meyer, J. W. Proksch,
S. T. Sonis, and K. W. Ward, “Topical application of the
synthetic triterpenoid RTA 408 protects mice from radiation-
induced dermatitis,” Radiation Research, vol. 181, no. 5,
pp. 512–520, 2014.
[76] J. S. Mehta, V. Kocaba, and Y. Q. Soh, “,e future of kera-
toplasty,” Current Opinion in Ophthalmology, vol. 30, no. 4,
pp. 286–291, 2019.
[77] L. A. Marraffini and E. J. Sontheimer, “CRISPR interference:
RNA-directed adaptive immunity in bacteria and archaea,”
Nature Reviews Genetics, vol. 11, no. 3, pp. 181–190, 2010.
[78] P. Mali, K. M. Esvelt, and G. M. Church, “Cas9 as a versatile
tool for engineering biology,” Nature Methods, vol. 10, no. 10,
pp. 957–963, 2013.
[79] E. D. Wieben, R. A. Aleff, X. Tang et al., “Trinucleotide repeat
expansion in the transcription factor 4 (TCF4) gene leads to
widespread mRNA splicing changes in fuchs’ endothelial
corneal dystrophy,” Investigative Opthalmology & Visual
Science, vol. 58, no. 1, pp. 343–352, 2017.
[80] C. Zarouchlioti, B. Sanchez-Pintado, N. J. Hafford Tear et al.,
“Antisense therapy for a common corneal dystrophy ame-
liorates TCF4 repeat expansion-mediated toxicity,” =e
American Journal of Human Genetics, vol. 102, no. 4,
pp. 528–539, 2018.
[81] J. Hu, Z. Rong, X. Gong et al., “Oligonucleotides targeting
TCF4 triplet repeat expansion inhibit RNA foci and mis-
splicing in fuchs’ dystrophy,” Human Molecular Genetics,
vol. 27, no. 6, pp. 1015–1026, 2018.
[82] Y. Q. Soh, G. S. Peh, and J. S. Mehta, “Evolving therapies for
fuchs’ endothelial dystrophy,” Regenerative Medicine, vol. 13,
no. 1, pp. 97–115, 2018.
[83] Y. K. Chang, J. S. Hwang, T.-Y. Chung, and Y. J. Shin, “SOX2
activation using CRISPR/dCas9 promotes wound healing in
corneal endothelial cells,” Stem Cells, vol. 36, no. 12,
pp. 1851–1862, 2018.
[84] L. Song, T. Llanga, L. M. Conatser, V. Zaric, B. C. Gilger, and
M. L. Hirsch, “Serotype survey of AAV gene delivery via
subconjunctival injection in mice,” Gene =erapy, vol. 25,
no. 6, pp. 402–414, 2018.
[85] L. Wang, R. Xiao, E. Andres-Mateos, and L. H. Vandenberghe,
“Single stranded adeno-associated virus achieves efficient gene
transfer to anterior segment in the mouse eye,” PLoS One,
vol. 12, no. 8, Article ID e0182473, 2017.
[86] M. Vicente-Pascual, A. Albano, M. Á. Solinı́s et al., “Gene
delivery in the cornea: in vitro & ex vivo evaluation of solid
lipid nanoparticle-based vectors,” Nanomedicine, vol. 13,
no. 15, pp. 1847–1854, 2018.
[87] A. Marcovich and O. Daphna, Treating Corneal Edema with
Artificial Corneal Endothelial Implant, EndoArt®: First Hu-man ExperienceEuropean Society of Cataract and Refractive
Surgeons, Athens, Greece, 2019.
[88] O. Daphna and A. Marcovich, Endoart: Innovative Artificial
Implant for Treating Corneal EdemaAmerican Society of
Cataract and Refractive Surgeons’ Congress, Boston, MA,
USA, 2020.
[89] M. Bruinsma, C. M. Tong, and G. R. J. Melles, “What does the
future hold for the treatment of fuchs endothelial dystrophy;
will “keratoplasty” still be a valid procedure?” Eye, vol. 27,
no. 10, pp. 1115–1122, 2013.
Journal of Ophthalmology 11
